Cynata Therapeutics Ltd. (OTCMKTS:CYYNF) Sees Large Growth in Short Interest

Cynata Therapeutics Ltd. (OTCMKTS:CYYNF) saw a significant increase in short interest during the month of April. As of April 30th, there was short interest totaling 4,327 shares, an increase of ∞ from the April 15th total of 0 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 4,273 shares, the days-to-cover ratio is currently 1.0 days.

Cynata Therapeutics Price Performance

CYYNF stock opened at $0.22 on Friday. Cynata Therapeutics has a 12 month low of $0.15 and a 12 month high of $0.22. The company has a 50-day moving average price of $0.22 and a 200 day moving average price of $0.18.

About Cynata Therapeutics

Cynata Therapeutics is a clinical‐stage biotechnology company specializing in the development of cell therapies using its proprietary Cymerus™ platform. The Cymerus process leverages induced pluripotent stem cells (iPSCs) to generate mesenchymal stem cells (MSCs) on a large scale, aiming to overcome the variability and supply challenges associated with donor‐derived MSCs. By utilizing a single, well‐characterized iPSC master cell bank, the company seeks to deliver consistent, off‐the‐shelf cell therapies for a range of inflammatory and degenerative conditions.

The company’s lead product candidate, CYP-001, is an iPSC‐derived MSC therapy being evaluated in a Phase 1 clinical trial for the prevention and treatment of acute graft‐versus‐host disease in patients undergoing hematopoietic stem cell transplantation.